Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Jubilant Pharmova Ltd. shows moderate revenue growth and decent profitability metrics compared to its peers in the pharmaceuticals sector, though it has the highest PE ratio, indicating potential overvaluation. Companies like Cipla and Dr. Reddy's stand out for their profitability and growth, while others like Divi's Laboratories face challenges with growth despite high profitability metrics. Overall, Jubilant Pharmova is positioned as a moderate growth player in a competitive landscape.
Leads in profitability metrics with a PE of 23.73 and strong revenue growth at 13.28% YoY.
High ROE (21.76%) and strong EPS growth (68.07) make it a top performer.
Significant revenue growth (18.12% YoY) and solid profitability metrics.